ProMIS Neurosciences (PMN) AI Stock Analysis

• Market Cap: $29.27M
• Dividend Yield: N/A
• Average Volume (3M): 14.63M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: N/A
• EPS Growth: 71.47%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.29
• Shares Outstanding: 51,806,496
• 10 Day Avg. Volume: 843,030
• 30 Day Avg. Volume: 14,633,773
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.42
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.46
• 1Y Price Target: $5.00
• Price Target Upside: 825.93% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 38 Underperform
• Price Target: ―

ProMIS Neurosciences faces significant financial hurdles, with no current revenue and ongoing operational losses, leading to a weak overall financial performance. The technical analysis indicates the stock is under pressure, and the valuation reflects challenges with a negative P/E ratio. While recent corporate events show promise in terms of future growth potential, they do not offset the immediate financial challenges. The overall score reflects the need for cautious optimism, as the company must improve its financials and achieve sustainable revenue generation.

Positive Factors

FDA Approval Process

The FDA has granted Fast Track designation to PMN310, potentially accelerating its approval process for treating Alzheimer's disease.

Market Opportunity

The Alzheimer's market presents a massive commercial opportunity, with a potential market exceeding $10 billion annually for an effective anti-amyloid antibody without ARIA risk.

Safety Profile

PMN310 shows no binding to amyloid plaque, unlike rival antibodies, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA).

Negative Factors

Dependency on Future Data

The upcoming first-in-patient P1b data in 2026 is a key catalyst and potential proof-of-concept for PMN310.

Funding Concerns

Pipeline seems interesting, but funding is an issue.

ProMIS Neurosciences Business Overview & Revenue Model

Company Description

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

How the Company Makes Money

ProMIS Neurosciences generates revenue through a combination of research and development collaborations, licensing agreements, and potential future sales of its proprietary therapeutics. The company may receive upfront payments, milestone payments, and royalties from its partnerships and licensing deals. Additionally, as its products advance through clinical development and potentially receive regulatory approval, ProMIS may earn revenue from product sales. The company's revenue model is highly dependent on successful clinical trials, strategic alliances, and partnerships with larger pharmaceutical companies to commercialize its therapies.

ProMIS Neurosciences Financial Statement Overview

Summary

ProMIS Neurosciences faces significant financial challenges, primarily due to an absence of revenue and consistent operational losses. While the balance sheet shows a strong equity position with no debt, cash flow issues and lack of revenue generation pose risks to long-term financial stability. Efforts to enhance revenue streams and manage cash flows more effectively are essential for improved financial health.

Income Statement

ProMIS Neurosciences shows a lack of revenue generation, with total revenue consistently at zero. The company's net profit margin is volatile due to irregular net income figures, and both EBIT and EBITDA margins remain negative, highlighting continued operational losses. The absence of revenue growth is a critical issue.

Balance Sheet

The balance sheet reveals a strong equity position with zero debt, resulting in a stable financial structure. However, the equity ratio fluctuates due to changes in total assets and liabilities. The return on equity is positive in the latest period, but historical volatility suggests instability in earning performance relative to equity.

Cash Flow

The cash flow statement indicates significant negative free cash flow, suggesting cash burn without offsetting revenue. Operating cash flow is consistently negative, reflecting difficulties in generating cash from operations. Despite high financing cash flow, sustainability remains a concern without revenue growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	―	―
Gross Profit	0.00	0.00	-10.44M	-21.78M	―	―
EBITDA	-8.43M	-16.83B	-17.81M	-29.88M	-9.33M	―
Net Income	-8.43M	2.78B	-17.51M	-12.74M	―	―
Balance Sheet
Total Assets	9.51M	18.91M	18.04M	9.38M	22.44M	1.38M
Cash, Cash Equivalents and Short-Term Investments	4.54M	13.32M	16.75M	8.01M	21.48M	1.11M
Total Debt	0.00	0.00	0.00	0.00	4.94M	0.00
Total Liabilities	9.89M	2.42M	13.07M	8.68M	15.28M	2.40M
Stockholders Equity	-382.58K	16.49M	4.97M	―	7.16M	-1.02M
Cash Flow
Free Cash Flow	-23.69M	-27.18M	-14.37M	-17.04M	―	―
Operating Cash Flow	-23.69M	-27.18M	-14.37M	-17.03M	―	―
Investing Cash Flow	-678.00	-693.00	―	-1.98K	94.33K	―
Financing Cash Flow	27.23M	27.88M	23.52M	6.49M	25.20M	3.01M

ProMIS Neurosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMN, the sentiment is Negative. The current price of 0.54 is below the 20-day moving average (MA) of 0.66, below the 50-day MA of 0.59, and below the 200-day MA of 0.73, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.12 is Neutral, neither overbought nor oversold. The STOCH value of 14.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PMN.

ProMIS Neurosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$19.22B	4.48	-1.43%	3.30%	11.19%	-15.58%
BOLT	52 Neutral	$9.39M	―	-81.33%	―	-62.68%	23.94%
CGTX	41 Neutral	$122.70M	―	-219.68%	―	―	29.58%
PMN	38 Underperform	$29.27M	―	-19.56%	―	―	71.47%
NERV	34 Underperform	$16.89M	1.64	>-0.01%	―	―	―
NRSN	30 Underperform	$28.05M	―	-2880.11%	―	―	31.09%
JUNS	―	$51.55M	―		―	―	―

ProMIS Neurosciences Corporate Events

ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial

On February 25, 2025, ProMIS Neurosciences announced the dosing of multiple patients in its Phase 1b PRECISE-AD clinical trial for PMN310, a drug candidate for Alzheimer’s disease. This milestone highlights the company’s commitment to addressing the urgent need for targeted AD therapies by selectively targeting toxic oligomers, a key driver of disease progression. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of PMN310, with interim results expected in the first half of 2026 and topline results in the second half of 2026. The trial’s design is expected to provide robust clinical data that could differentiate PMN310 from other AD treatments, potentially offering a more effective and well-tolerated option for patients.

ProMIS Neurosciences Announces COO Position Termination

On February 14, 2025, ProMIS Neurosciences Inc. announced the separation of Gavin T. Malenfant from his role as Chief Operating Officer, coinciding with the termination of the COO position without plans for a replacement. This move reflects a strategic shift that could impact the company’s operational structure and potential cost-saving measures, influencing both internal efficiencies and external perceptions.